SARS, MERS and COVID-19, the story continues
| Author | Ata Mahmoodpoor | en |
| Orcid | Ata Mahmoodpoor [0000-0002-4361-6230] | en |
| Issued Date | 2020-06-30 | en |
| Abstract | Although the three viruses corona viruses (SARS-CoV: 2003, MERS-CoV: 2012 and SARS-CoV-2: 2019) have similarities especially regarding clinical features, there are key differences between them that limit the relevance of experiences from previous crises. Regarding treatment in the absence of vaccine, it is recommended an the first stage to use pharmaceuticals and their combinations (protease inhibitors, interferon compounds, antiviral antibodies) aiming to suppress diverse targets during virus propagation and during the second disease stage, it seems crucial and reasonable to rely on administration of pathogenetic drugs to restrict life threatening events resulting in marked inflammation, intoxication, hypoxia and infection. The most important method to prevent viral zoonosis is to maintain the barriers between natural reservoirs and human society. | en |
| DOI | https://doi.org/10.22037/jcma.v5i2.31196 | en |
| Keyword | SARS; | en |
| Keyword | MERS; | en |
| Keyword | COVID-19; | en |
| Publisher | Brieflands | en |
| Title | SARS, MERS and COVID-19, the story continues | en |
| Type | Editorial | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 125150.pdf
- Size:
- 272.49 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF